Indeed, the currently approved first-line treatment for advanced HCC include the combination of anti-PD-L1 antibody atezolizumab and anti-VEGF antibody bevacizumab, and the IMbrave150 clinical trial, which demonstrated its superiority over sorafenib in terms of OS and PFS, was performed in treatment-naïve patients [21]. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.